Bupropion for Weight Loss: Dose, Mechanism, and How It Compares to GLP-1 Medications

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 13 sources cited

Key Takeaways

• Bupropion alone produces about 5 to 10 lb (2 to 4.5 kg) weight loss over 6 to 12 months at doses of 300 to 400 mg per day, mostly via reduced appetite and mild stimulation.
• Bupropion + naltrexone (the combination sold as Contrave) produces about 5 to 10% body weight loss at 56 weeks (Greenway et al., Lancet 2010), roughly twice the effect of bupropion alone.
• The mechanism: bupropion increases dopamine and norepinephrine in the hypothalamic appetite center, while naltrexone blocks the negative feedback loop that normally limits the effect.
• Compared with GLP-1 medications (semaglutide 14.9% loss, tirzepatide 22.5%), bupropion-based therapy produces less than half the weight reduction.
• Bupropion is a reasonable option for patients with depression plus obesity, smokers trying to quit, or patients who cannot tolerate GLP-1 medications.

Direct answer (40-60 words)

Bupropion (Wellbutrin) produces about 5 to 10 lb weight loss over 6 to 12 months at 300 to 400 mg per day, mostly through appetite suppression and mild stimulation. Combined with naltrexone (Contrave), the effect doubles to about 5 to 10% body weight loss at 56 weeks. Both are smaller than GLP-1 medications but still meaningful.

Table of contents

1. The 30-second answer
2. How bupropion produces weight loss
3. Bupropion alone vs bupropion + naltrexone (Contrave)
4. Dose and titration
5. Timeline: when weight starts coming off
6. Who responds best
7. Side effects and risks
8. Bupropion vs GLP-1 medications
9. Drug interactions and contraindications
10. FAQ
11. Sources
12. Footer disclaimers

How bupropion produces weight loss

Bupropion is an atypical antidepressant that selectively inhibits the reuptake of dopamine and norepinephrine in the central nervous system. It does not act on serotonin (which is why it does not cause the weight gain typical of SSRI antidepressants).

The weight-loss mechanism has three components:

1. Reduced appetite via hypothalamic POMC neurons. Bupropion activates pro-opiomelanocortin neurons in the arcuate nucleus, which signal satiety. Patients eat less without feeling deprived.

2. Mild stimulant effect. Bupropion's noradrenergic activity produces a small increase in resting energy expenditure (about 1 to 2%) and reduces fatigue, which can support more physical activity.

3. Reduced food cravings. The dopaminergic effect blunts the reward response to highly palatable food. Patients on bupropion often report less interest in sweets, salty snacks, and binge-eating triggers.

A 2002 trial (Anderson et al., Obesity Research) showed bupropion 300 to 400 mg per day produced 4.6 to 5.1 kg weight loss at 24 weeks vs 1.3 kg on placebo. The effect plateaued after about 6 months, which is the typical pattern for a single-mechanism appetite suppressant.

Bupropion alone vs bupropion + naltrexone (Contrave)

Naltrexone is an opioid receptor antagonist used for alcohol and opioid dependence. Alone, it has minimal weight effect. Combined with bupropion, it amplifies the weight-loss signal in a specific way.

The combination works because bupropion-stimulated POMC neurons normally release both alpha-MSH (the satiety signal) and beta-endorphin (an opioid that feeds back to inhibit POMC activity). Naltrexone blocks the beta-endorphin feedback, allowing the satiety signal to keep firing.

The COR-I trial (Greenway et al., Lancet 2010) compared bupropion 360 mg + naltrexone 32 mg per day to placebo over 56 weeks in 1,742 adults with obesity:

The 32 mg + 360 mg dose is the FDA-approved Contrave formulation. The 5 to 10% body weight loss range across COR-I, COR-II, COR-BMOD, and COR-DM trials is the modern benchmark for bupropion-naltrexone therapy.

A few practical points:

• Bupropion alone is typically prescribed off-label for weight loss when patients also have depression or are quitting smoking. The weight loss is meaningful but smaller (4 to 5 kg).
• Contrave is FDA-approved specifically for chronic weight management in adults with BMI 30+, or BMI 27+ with weight-related comorbidities.
• The combination is contraindicated with opioid use, which is the most common reason patients cannot take it.

Dose and titration

Bupropion alone for weight loss (off-label):

• Bupropion SR (sustained-release): start 150 mg every morning for 7 days, then increase to 150 mg twice daily.
• Bupropion XL (extended-release): start 150 mg every morning for 7 days, then increase to 300 mg every morning. Some clinicians push to 450 mg if tolerated.
• Maximum dose: 450 mg per day. Higher doses substantially increase seizure risk.

Contrave (bupropion + naltrexone) titration:

• Week 1: 1 tablet (8 mg naltrexone / 90 mg bupropion) every morning
• Week 2: 1 tablet morning + 1 tablet evening
• Week 3: 2 tablets morning + 1 tablet evening
• Week 4 and onward: 2 tablets morning + 2 tablets evening (maintenance dose: 32 mg naltrexone / 360 mg bupropion daily)

Slow titration reduces nausea, headache, and insomnia, which are the most common reasons patients stop the drug. Most adverse effects peak in weeks 1 to 4 and improve as the dose stabilizes.

Timeline: when weight starts coming off

Patients who lose less than 5% of body weight by 12 to 16 weeks on Contrave generally do not see further benefit from continued therapy and are advised to discontinue. The same rough rule applies to off-label bupropion: if the scale has not moved at 16 weeks, the medication is unlikely to be the right fit.

Who responds best

Bupropion-based weight loss tends to work best in:

• Patients with co-existing depression or seasonal affective disorder. Treating both at once is efficient.
• Smokers trying to quit. Bupropion is FDA-approved for smoking cessation under the brand Zyban. Quitting smoking with bupropion typically prevents the 5 to 10 lb weight gain that accompanies cessation.
• Patients who report strong food cravings, especially for carbohydrates and sweets.
• Patients who feel fatigued or low-energy on diets, where bupropion's mild stimulant effect is welcome.
• Patients with mild to moderate obesity (BMI 30 to 40) who have not yet tried GLP-1 therapy.

Smaller effects in:

• Patients with primarily binge-eating-disorder pattern (bupropion can help, but lisdexamfetamine has stronger BED data).
• Patients with severe obesity (BMI 40+), where the magnitude of weight loss is not enough to address comorbid disease.
• Patients without significant cravings or appetite issues, where the mechanism does not target the actual problem.

Side effects and risks

Common side effects (10 to 30% of patients):

• Insomnia and vivid dreams (most common; minimize by taking morning doses, not evening)
• Dry mouth
• Headache
• Nausea (especially with Contrave's naltrexone component)
• Constipation (Contrave more than bupropion alone)
• Dizziness
• Increased heart rate (mild, usually 5 to 10 bpm)
• Increased blood pressure (mild, usually 1 to 3 mmHg)

Less common but serious:

• Seizures. Bupropion lowers seizure threshold. The risk is roughly 0.1% at 300 mg, 0.4% at 450 mg, and substantially higher above 450 mg. Patients with history of seizures, eating disorders (which alter electrolytes), or alcohol withdrawal should not take bupropion.
• Mood changes. Like all antidepressants, bupropion carries an FDA black-box warning for suicidal ideation in patients under 25.
• Hypertensive episodes in patients with poorly controlled blood pressure.
• Mania in patients with undiagnosed bipolar disorder.
• Hepatotoxicity (rare; LFT monitoring at baseline and 6 months is reasonable for Contrave).

Discontinuation: bupropion does not have a meaningful withdrawal syndrome. Stopping abruptly is not associated with rebound depression or anxiety in most patients. Naltrexone can also be stopped without taper.

Bupropion vs GLP-1 medications

Bupropion-based therapy lands at the lower end of FDA-approved options. It is meaningfully smaller than GLP-1 medications, but it is also cheaper, available as a generic, and useful for patients with comorbid depression or smoking cessation goals. Patients who do not tolerate GLP-1 medications (severe nausea, gastroparesis history, family history of medullary thyroid carcinoma) often do well on bupropion-based therapy.

Internal link: For an overview of how GLP-1 medications work, see how GLP-1 receptor agonists work.

Drug interactions and contraindications

Absolute contraindications for bupropion:

• History of seizure disorder
• Active or recent eating disorder (anorexia, bulimia)
• Concurrent MAOI use (or within 14 days of stopping)
• Abrupt discontinuation of alcohol or sedatives
• Known hypersensitivity to bupropion

Additional contraindications for Contrave (bupropion + naltrexone):

• Chronic opioid use (naltrexone precipitates withdrawal)
• Uncontrolled hypertension
• Pregnancy

Important interactions:

• CYP2D6 substrates. Bupropion is a strong CYP2D6 inhibitor. Drugs metabolized by CYP2D6 (codeine, tramadol, tamoxifen, some beta-blockers) may have altered levels. Tramadol is particularly worth flagging because reduced metabolism increases serotonin syndrome risk.
• MAOIs. Hypertensive crisis risk. Wait 14 days after stopping an MAOI before starting bupropion.
• Alcohol. Can lower seizure threshold further. Moderate use is not contraindicated but heavy use is.
• Other antidepressants. Combining bupropion with SSRIs is common and generally safe. Combining with SNRIs (duloxetine, venlafaxine) requires more caution due to noradrenergic stacking.
• Stimulants (amphetamines). Combination is sometimes done for ADHD plus depression but raises BP and seizure risk.

Internal link: For a side-by-side of weight loss medications including non-GLP-1 options, see comparing weight-loss medications.

FAQ

How much weight can I lose on bupropion alone? Most patients lose 5 to 10 lb (2 to 4.5 kg) over 6 to 12 months on bupropion 300 to 400 mg per day. The biggest losses happen in the first 4 to 6 months, with a plateau after that. Bupropion is FDA-approved for depression and smoking cessation, not weight loss, so this is off-label use.

How much weight can I lose on Contrave? Average weight loss on Contrave is 5 to 10% of starting body weight at 56 weeks (about 12 to 25 lb for someone starting at 250 lb). About half of patients hit at least 5% loss. The trial data comes from the COR-I, COR-II, COR-BMOD, and COR-DM trials.

How long does bupropion take to start working for weight loss? Reduced appetite often begins in week 1 to 2. The first measurable weight loss usually shows up at week 4 to 6. The full effect develops over 4 to 6 months. If the scale has not moved at 16 weeks, the medication is unlikely to work for you.

Is bupropion better than Wegovy or Zepbound for weight loss? No, in terms of magnitude. GLP-1 medications produce 14 to 22% weight loss at 56 to 72 weeks vs 5 to 10% on Contrave. Bupropion-based therapy is more useful for patients with comorbid depression, smoking cessation goals, or contraindications to GLP-1 medications.

Can I take bupropion with Wegovy or Zepbound? Yes, with provider supervision. There are no direct drug interactions. Combination therapy is sometimes used in patients who plateau on a GLP-1 alone. Side effect monitoring (especially blood pressure and mood) is more important when combining.

What dose of bupropion is best for weight loss? The trial data supports 300 to 400 mg per day for off-label weight loss. For Contrave, the FDA-approved dose is 32 mg naltrexone + 360 mg bupropion daily. Higher bupropion doses (above 450 mg) increase seizure risk without proportional weight benefit.

Does bupropion reduce food cravings? Yes. The dopaminergic effect blunts the reward response to highly palatable food. Patients commonly report less interest in sweets, salty snacks, and the kind of food that drives binge eating. The craving effect is one of the most consistent subjective reports.

Will bupropion keep me up at night? Sometimes. Insomnia and vivid dreams are the most common side effects, especially with the XL formulation. Taking the dose in the morning (and the second dose by early afternoon for SR) usually solves it. Patients with pre-existing insomnia may want to discuss alternatives.

Can bupropion cause weight gain? Rarely. Bupropion is one of the few antidepressants that is weight-neutral or weight-negative on average. SSRIs (sertraline, paroxetine, citalopram) tend to cause modest weight gain over months. Bupropion does not.

Is Contrave covered by insurance? Coverage varies. Some commercial plans cover Contrave with prior authorization. Medicare and Medicaid generally do not cover it. Cash price for Contrave is roughly $700 per month at major pharmacies; manufacturer savings cards can reduce this substantially.

Can I drink alcohol on bupropion? Moderate alcohol is not strictly contraindicated, but heavy or binge drinking lowers seizure threshold further. Most providers recommend limiting to 1 to 2 drinks per occasion and avoiding daily use. Patients with alcohol use disorder should not take bupropion at all.

Should I stop bupropion if I am not losing weight? At 12 to 16 weeks, if you have not lost at least 5% of body weight, the medication is unlikely to be effective for you. Talk to your provider about discontinuation or a switch to a different class. Continuing past that point typically does not produce more weight loss.

Sources

1. Greenway FL, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): randomised controlled trial. Lancet. 2010;376:595-605.
2. Apovian CM, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21:935-943.
3. Wadden TA, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: COR-BMOD. Obesity. 2011;19:110-120.
4. Hollander P, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes (COR-DM). Diabetes Care. 2013;36:4022-4029.
5. Anderson JW, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res. 2002;10:633-641.
6. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
7. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
8. Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). N Engl J Med. 2015;373:11-22.
9. Hurt RD, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-1202.
10. FDA prescribing information, Contrave (naltrexone HCl and bupropion HCl extended release tablets).
11. FDA prescribing information, Wellbutrin XL (bupropion hydrochloride extended-release tablets).
12. Apovian CM, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342-362.
13. Khera R, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: systematic review and meta-analysis. JAMA. 2016;315:2424-2434.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wellbutrin, Wellbutrin XL, Wellbutrin SR, Zyban, and Contrave are registered trademarks of their respective owners. Wegovy, Zepbound, and Saxenda are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.